<DOC>
	<DOCNO>NCT00003270</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Umbilical cord blood transplantation may allow doctor give high dos chemotherapy radiation therapy kill cancer cell . PURPOSE : Phase II trial study effectiveness chemotherapy , radiation therapy , umbilical cord blood transplantation treat patient hematologic cancer .</brief_summary>
	<brief_title>Chemotherapy , Radiation Therapy , Umbilical Cord Blood Transplantation Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety , efficacy , toxicity use cord blood source stem cell transplantation patient hematologic malignancy . OUTLINE : Patients undergo autologous bone marrow harvest peripheral stem cell collection prior transplant regimen , unless patient acute leukemia relapse , aplastic anemia , myelodysplastic syndrome . Arm I : Patients eligible undergo total body irradiation ( TBI ) first receive cyclophosphamide IV 2 hour day -5 -4 , undergo TBI twice day day -3 -1 . Patients also receive antithymocyte globulin ( ATG ) IV 10 hour day -3 -1 . Cord blood infuse day 0 . Arm II : Patients eligible receive TBI receive oral busulfan every 6 hour day -7 -4 total 16 dos . Cyclophosphamide , ATG , cord blood administer arm I . All patient receive cyclosporine day -2 180 , methylprednisolone day 5-180 , filgrastim ( G-CSF ) day 1 . Patients follow weekly day 180 monthly 2 year . PROJECTED ACCRUAL : A total 20 patient ( 10 patient per arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove hematologic malignancy Acute lymphocytic leukemia ( ALL ) : In second late remission In first remission poor prognostic feature ( Philadelphia chromosome positive ) Acute myeloid leukemia ( AML ) : In second late remission In first remission poor prognostic feature , e.g. , Arising myelodysplastic syndrome Cytogenetics 5 , 7 , +8 , 11q23 abnormality Complex cytogenetics AML ALL refractory induction relapse Myelodysplastic syndrome Chronic myelogenous leukemia Severe aplastic anemia Fanconi 's anemia Relapsed Hodgkin 's disease Relapsed nonHodgkin 's lymphoma Multiple myeloma No suitable family donor match 5 6 HLA antigen ( A , B , DR ) No suitable unrelated donor match 6 HLA antigen Cord blood donor available match 46 6 HLA antigen PATIENT CHARACTERISTICS : Age : 5 50 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 3 time normal Alkaline phosphatase less 3 time normal SGOT le 3 time normal Renal : Creatinine le 2 time normal OR Creatinine clearance great 60 mL/min Cardiovascular : MUGA ejection fraction least 50 % Pulmonary : DLCO spirometry least 60 % OR Exercise VO2 max/kg least 15 mL/min/kg Other : HIV antibody negative Hepatitis B surface antigen negative No active bacterial , viral , fungal infection PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow If follow limit exceed , patient may receive total body irradiation : No prior radiation one entire kidney Whole liver receive great 1000 cGy No prior whole abdomen radiotherapy Small bowel receive great 3000 cGy Heart receive great 1800 cGy No prior whole lung radiotherapy CNS receive less 30 cGy ( whole brain portion spine ) Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>